Calidi Biotherapeutics logo
Calidi Biotherapeutics
CLDI | AMEX
Chart Builder DCF Calculator
$0.59
-$0.03 (-5.13%)
At close: Nov 16, 2026, 3:59 PM ET
$0.58
-$0.01 (-0.85%)
After-hours: Nov 16, 2026, 5:13 PM ET

Calidi Biotherapeutics Company Profile

Company profile explained

Company Profile

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.

Key Executives

Name Position
Eric E. Poma Chief Executive Officer & Director
Andrew C. Jackson Chief Financial Officer & Corporate Secretary
Antonio Fernandez Santidrian Head of Technical Operations & Chief Scientific Officer
Guy Travis Clifton Chief Medical Officer

Latest SEC Filings

Date Type Title
Sep 25, 2026 8-K Current Report
Sep 22, 2026 8-K Current Report
Sep 17, 2026 424B5 Filing
Aug 19, 2026 4 Filing
Aug 19, 2026 4 Filing
Aug 19, 2026 4 Filing
Aug 19, 2026 4 Filing
Aug 19, 2026 4 Filing
Aug 19, 2026 4 Filing
Aug 19, 2026 4 Filing
View All SEC Filings ➞
Calidi Biotherapeutics
Calidi Biotherapeutics logo
Country United States
IPO Date Nov 1, 2021
Industry Biotechnology
Sector Healthcare
Employees 29
CEO Eric E. Poma

Contact Details

4475 Executive Drive San Diego, California 92121 United States

Stock Details

Ticker Symbol CLDI
Exchange AMEX
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001855485
CUSIP Number 320703507
ISIN Number US3207035078
SIC Code 6770

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.